Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-25-206494

Chief Operating Officer sold 45,783 shares at an average $114.48 ($5,241,127)

  • Chief Operating Officer acquired 40,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Jacobson Mark L. Chief Operating Officer 2025-09-16 Sale 10b5-1 −5,783 $116.19 $671,927 0 D: show line 1 in the form
Jacobson Mark L. Chief Operating Officer 2025-09-16 Option exercise 10b5-1 +25,000 $4.95 $123,750 25,000 D: show line 2 in the form
Jacobson Mark L. Chief Operating Officer 2025-09-16 Option exercise 10b5-1 +15,000 $4.85 $72,750 40,000 D: show line 3 in the form
Jacobson Mark L. Chief Operating Officer 2025-09-16 Sale 10b5-1 −40,000 $114.23 $4,569,200 0 D: show line 4 in the form
Open-market sales · 45,783 sh · avg $114.48 · $5,241,127

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Jacobson Mark L. Chief Operating Officer 2025-09-16 Option exercise · Stock Option (Right to Buy) 10b5-1 −25,000 0 D: show line 5 in the form
Jacobson Mark L. Chief Operating Officer 2025-09-16 Option exercise · Stock Option (Right to Buy) 10b5-1 −15,000 0 D: show line 6 in the form
Loading xslF345X05/ownership.xml…